logo-loader

ReNeuron seeing increased interest across its assets from potential licensee partners

Published: 11:42 11 Jan 2019 EST

ReNeuron Group PLC (LON: RENE) CFO Michael Hunt sat down with Proactive Investors at the 11th Annual Biotech Showcase in San Francisco.

The UK-based developer of cell-based therapeutics in is the U.S. engaging with U.S. investors, and is looking to build out its business development activity.

ReNeuron has extended cash runway as it focuses on validating its exosome...

ReNeuron Group PLC (AIM:RENE, OTC:RNUGF) executive chairman Iain Ross tells Proactive that the company is focused on generating in vivo data and validating its exosome delivery technology platform CustomEX as 2023 gets underway. ReNeuron will conduct head-to-head studies with its competitors...

on 02/17/2023